The studies show that JAK inhibitors and other small molecules are capable of reawakening dormant hair follicles and stem cell therapies that can develop new follicles.

The first study was led by Angela Christiano, whos a professor of Dermatology at Columbia University Vagelos College of Physicians and Surgeons. The researchers discovered some previously unknown cells that ensure that mouse hair follicles dont leave a resting state. If the activities of these cells are inhibited, dormant follicles can be reawakened.

In the second research, the team of Christiano found a method for growing human hair in a dish. This method could make more men and women start exploring the idea of hair restoration surgery. It could also enhance the method that pharmaceutical companies consider when looking for new hair-growth medications.

In pattern baldness, lots of hair follicles are still in existence. However, they are dormant. The focus of researchers on getting drugs that function effectively in the same pathways as minoxidil and finasteride has affected their quest to find new drugs that can reawaken follicles and inhibit hair growth. Notably, minoxidil and finasteride are the only two medications that can be used by men suffering from male pattern baldness.

The researchers had previously found a new pathway, known as JAK-STAT, which is active in the stem cells of resting hair follicles and makes them remain in a state of dormancy. Christiano and other researchers in his team showed that JAK inhibitors used on mouse skin are good for reawakening resting follicles in mice.

Their second study was targeted at knowing more about the natural processes of making sure that the follicles remain dormant. Therefore, the researchers searched for factors that managed the activity of the JAK pathway in the hair follicle.

During the search, the Colombian researchers found a formerly unknown immune-related cell type that is capable of creating a substance called Oncostatin M. This substance makes sure that the follicle doesnt leave a dormant state. One of the authors of the study, Etienne Wang, Ph.D., notes Rare subsets of immune cells were previously difficult to identify in a whole skin, but this work was facilitated by our ability to sequence individual cells and pinpoint the ones making Oncostatin M.

There are some resemblances between these cells and macrophages, which are regarded as the immune systems scavenger cells. The researchers discovered that these cells are close to resting hair follicles.

These cells have been named trichophages. It should be noted that this name is taken from tricho, which is a Greek word for hair.

Besides, the hair cycle could be turned on when the trichophages are being targeted. By utilizing antibodies and small molecular inhibitors for inhibiting Csf1R, which is a receptor that is found on the trichophages, the flow of Oncostatin M could be blocked so that the hair cycle can start once again.

The second study involved the creation of a means of growing human hair in a dish. This method could lead to hair restoration surgery for an increased number of individuals including women. This new development could also enhance the method through which pharmaceutical companies find new hair growth medications.

It is worthwhile to note that this study brings a novel idea of growing human hair follicles in a dish without using any implantation in the skin.

Notably, researchers have been generating new rat or mouse hairs by culturing cells that were extracted from the end of existing follicles.

To find a way around human hair cells resistance, the Colombian researchers have been looking for ways to build conditions that look like the 3D environment that is the habitat of human hair cells. Although they failed at the beginning, they are making progress now as they have found a way to grow new human hair follicles in a dish in a lab.

In a nutshell, these new approaches can bring a significant change to the process of dealing with hair loss in both men and women. While studies are still going on, you can cope with your hair loss by picking the right products at Lilyhair.co.uk to improve your overall look.

Continue reading here:
Studies uncover new approaches to combat hair loss in men and women - Business MattersBusiness Matters

Skin Stem Cells Comments Off on Studies uncover new approaches to combat hair loss in men and women – Business MattersBusiness Matters | July 8th, 2020

Stem cells have been holding great promise for regenerative medicine for ages. In the last decade, many studies have revealed this form of cell, which in Spanish is calledmother cell due to its ability to contribute to various different cell types, may be applied in regenerative medicine to diseases such as muscle and nervous system disorders, among others.

Scientists and stem cell leaders Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea.

However, one of the key constraints in the application of these herbal remedies is the caliber of the stem cells that may be made in the lab, which impedes their use for curative purposes.

Currently, a team in the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), headed by researcher Marcos Malumbres, has recently developed a fresh, easy and fast technology that enhances in vitro and in vivo the possibility of stem cells to differentiate into adult cells. The study results will be released this week in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have.The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types.Mara Salazar-Roa, Study First Author and Researcher, Centro Nacional de Investigaciones Oncolgicas

Roa is likewise the co-corresponding author of this analysis.

Within this study, the researchers identified an RNA sequence, called microRNA 203, that can be found at the earliest embryonic stages before the embryo implants in the uterus and when stem cells have their highest ability to generate all the different cells.When they added this molecule to stem cells from the laboratory, they discovered that the cells ability to convert into other cell types improved appreciably.

To corroborate them, they used stem cells of both human and murine origin, and of genetically altered mice. The results were so spectacular, both in mouse cells and in human cells

Application of the microRNA for just 5 days boosts the potential of stem cells in most situations we tested and improves their ability to become other specialised cells, even months after being connected with the microRNA. Says Salazar-Roa.

According to the research, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the doorway to a better generation of different cell types essential for the cure of degenerative disorders.

Malumbres, mind of the CNIO Cell and Cancer Division Group, states:To deliver this asset to the clinic, cooperation with labs or companies that are looking to exploit that technology is now essential in each particular case.

In this circumstance, Salazar-Roa recently participated, in close collaboration with all the CNIOs Innovation group, in prestigious creation programs like IDEA2 International of the Massachusetts Institute of Technology (MIT) and also CaixaImpulse of thisLa Caixa Foundation, where they also obtained funding to start the maturation of the technology.

See more here:
New technology May Raise the quality of stem cells Found in regenerative medicine - Microbioz India

Cardiac Stem Cells Comments Off on New technology May Raise the quality of stem cells Found in regenerative medicine – Microbioz India | July 8th, 2020

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Medicinal Fungi Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Medicinal Fungi market.

The research study includes the latest updates about the COVID-19 impact on the Medicinal Fungi sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Medicinal Fungi manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=212882&utm_source=3WN&utm_medium=888

The Medicinal Fungi market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Medicinal Fungi market.

This study analyzes the growth of Medicinal Fungi based on the present, past and futuristic data and will render complete information about the Medicinal Fungi industry to the market-leading industry players that will guide the direction of the Medicinal Fungi market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Medicinal Fungi market. Additionally, it includes a share of each segment of the Medicinal Fungi market, giving methodical information about types and applications of the market.

Reasons for Buying Medicinal Fungi Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Medicinal Fungi market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=212882&utm_source=3WN&utm_medium=888

In the end, the Medicinal Fungi market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Medicinal Fungi market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Yohimbine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeaxanthine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeolite Powder Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeolites Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zinc Acetylacetonate Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Medicinal Fungi Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Cardiac Stem Cells Comments Off on Medicinal Fungi Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News | July 8th, 2020

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Hematopoietic Stem Cells Transplantation Market which would mention How the Covid-19 is affecting the Hematopoietic Stem Cells Transplantation Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Hematopoietic Stem Cells Transplantation Players to Combat Covid-19 Impact.

Hematopoietic stem cell transplantation (HSCT) includes the intravenous infusion of autologous or allogeneic stem cells composed from bone marrow, or umbilical cord blood, peripheral blood to reestablish hematopoietic purpose in patients whose bone marrow or immune system is dented or flawed.

Request for sample report:

https://www.reportconsultant.com/request_sample.php?id=70734

Report Consultant has recently added a new Report on Hematopoietic Stem Cells Transplantation Market into its largest Database. It gives the complete report on trends, growth, and opportunity, restraint. Along with this, it delivers a comprehensive description of the key players of different regions.

Leading Players Hematopoietic Stem Cells Transplantation Market:

Escape Therapeutics, Lonza Group, Regen BioPharma Inc, Cesca Therapeutics Inc., Cryo-Save AG, CBR Systems, Inc., Pluristem Therapeutics Inc., China Cord Blood Corporation, and ViaCord Inc.

It contains an enormous database containing numerous market segments and sub-segments. The study also provides importance on the latest daises along with the effect of certain platforms on market growth.

Ask for Discount on This Report:

https://www.reportconsultant.com/ask_for_discount.php?id=70734

Market Segmentation: The market is segmented on the basis of type, application, and region.

Market Segmentation by Type:

Market Segmentation by Application:

Market Segmentation by Regions:

To achieve this, the Report Consultant has given prime importance to the exploration techniques for global clients and potential clients. Reaching out towards global clients has become a vital part to succeed in the Hematopoietic Stem Cells Transplantation Market. It offers SWOT analysis to identify the various significant business parameters such as strengths, weaknesses, threats, and opportunities which support to decision-makers to formulate the data-driven decisions in businesses.

Buy an exclusive Report:

https://www.reportconsultant.com/checkout?id=70734

Reasons for buying this research report:

About us:

Report Consultant A global leader in analytics, research, and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations, and information using our experienced skills and verified methodologies.

Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:

Rebecca Parker

(Report Consultant)

Contact No: +81-368444299

[emailprotected]

http://www.reportconsultant.com

Read the original:
Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen...

Bone Marrow Stem Cells Comments Off on Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen… | July 8th, 2020

LONDON, July 6, 2020 /PRNewswire/ -- IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1

The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.

Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."

It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.

Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."

"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem," concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.

More About the Study1

In addition to this research, IVI are presenting three more studies at the ESHRE Congress:

These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7

More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients

To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.

IVIRMA Global and IVI London, UK

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.comhttps://ivi-fertility.co.uk/

References

Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg

Read more here:
Breakthrough study demonstrates the 're-awakening' of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -...

Bone Marrow Stem Cells Comments Off on Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -… | July 8th, 2020

One cancer survivor looks at all the ways they might have gotten cancer, and wonders if any of those risk factors will factor into recurrence.

William Ramshaw resides in the expansive Pacific Northwest. He is a six-year survivor of pancreatic cancer and has written a memoir Gut Punched! Facing Pancreatic Cancer.

So, what would someone do to get cancer?

Use tobacco. Both my parents smoked packs a day. My brother chews. One of my best friends chain-smoked. I used to tell him, Dennis, this is going to kill you. He laughed. It did. Lost to esophageal cancer. Given those ominous Surgeon Generals Warnings, all caps and bolded, along with horrendous TV infomercials, I am mystified why people still use tobacco, but they do. Nicotine addiction is an awful thing.

Being overweight. Ok, this one is closer to home. Before getting pancreatic cancer, I had been a big guy. Not blimp-sized mind you but carrying pounds I didnt need. Post-surgery, I lost a third of my body weight, about 100 pounds. I have no butt. Yes, I can now wear those skinny jeans. Also, due to being replumbed, I cant even gain weight. Still, I wouldnt recommend my weight loss program to anyone. Its barbaric.

Getting too much sun. Growing up I plowed our orchard in my cutoffs with no shirt. By the end of summer, I was toasted brown. Looking back, I hope the layer of dirt shielded me from getting too many rays. Excess UV light is known to cause skin cancer. So far so good. I dont have any skin lesions yet.

Exposure to bad stuff. It seems everything I buy anymore comes with a warning such-and-such may cause cancer. I do pay attention but find myself unable to avoid exposure to everything that might be bad for me. At this point, I think breathing causes cancer. Should I stop breathing?

Breathing asbestos. Im a goner here too. As a former Navy-guy, I worked down in the boiler room. Hot as hell right there among gigantic steam pipes all encased in asbestos. Thankfully, so far, I have nothing other than a persistent cough and no lung cancer.

Worse draw an inside straight. (Also known as a gutshot or belly buster draw, where you have a straight but are missing the card in the middle.) While I dont play poker, getting cancer is a lot like drawing an inside straight. Our genes get messed up. Maybe we got them from a long-dead ancestor. One clicks over and we find ourselves with a losing cancer hand. Im not sure what happened in my case. My tumor was not genetically profiled. I wish it had been so I would better understand my odds at this point. Will I get another shot at a losing hand?

I know this in jest as no one tries or wants to get cancer. But its interesting to think about everything that causes cancer. Sadly, there are dozens of things. Cancer aside, I am indeed fortunate (and thankful) to be here.

Read more:
Seven 'Sure' Ways to Get Cancer - Curetoday.com

Bone Marrow Stem Cells Comments Off on Seven ‘Sure’ Ways to Get Cancer – Curetoday.com | July 8th, 2020

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:86172.

CAS PubMed Article Google Scholar

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:66376.

CAS PubMed Article Google Scholar

Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature. 2009;461:914.

CAS PubMed Article Google Scholar

Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell. 2009;5:1358.

CAS PubMed Article Google Scholar

Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS cells produce viable mice through tetraploid complementation. Nature. 2009;461:8690.

CAS PubMed Article Google Scholar

Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:11530.

CAS PubMed Article Google Scholar

Hasegawa K, Pomeroy JE, Pera MF. Current technology for the derivation of pluripotent stem cell lines from human embryos. Cell Stem Cell. 2010;6:52131.

CAS PubMed Article Google Scholar

Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond Ser B Biol Sci. 2011;366:231222.

CAS Article Google Scholar

Devolder K. To be, or not to be? Are induced pluripotent stem cells potential babies, and does it matter? EMBO Rep. 2009;10:12857.

CAS PubMed PubMed Central Article Google Scholar

Fadel HE. Developments in stem cell research and therapeutic cloning: Islamic ethical positions, a review. Bioethics. 2012;26:12835.

PubMed Article Google Scholar

Abad M, Mosteiro L, Pantoja C, Canamero M, Rayon T, Ors I, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013;502:3405.

CAS PubMed Article Google Scholar

Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009;27:10506.

CAS PubMed PubMed Central Article Google Scholar

Hentze H, Soong PL, Wang ST, Phillips BW, Putti TC, Dunn NR. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. 2009;2:198210.

PubMed Article Google Scholar

Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther. 2014;9:6372.

CAS PubMed PubMed Central Article Google Scholar

Simonson OE, Domogatskaya A, Volchkov P, Rodin S. The safety of human pluripotent stem cells in clinical treatment. Ann Med. 2015;47:37080.

PubMed Article Google Scholar

Ayala FJ. Cloning humans? Biological, ethical, and social considerations. Proc Natl Acad Sci U S A. 2015;112:887986.

CAS PubMed PubMed Central Article Google Scholar

Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11:14752.

CAS PubMed Article Google Scholar

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:40912.

CAS PubMed Article Google Scholar

Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. 2008;105:28838.

CAS PubMed PubMed Central Article Google Scholar

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:191720.

CAS PubMed Article Google Scholar

Sayed N, Liu C, Wu JC. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J Am Coll Cardiol. 2016;67:216176.

PubMed PubMed Central Article Google Scholar

Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10:67884.

CAS PubMed Article Google Scholar

Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17:194200.

CAS PubMed Article Google Scholar

Eguchi T, Kuboki T. Cellular reprogramming using defined factors and microRNAs. Stem Cells Int. 2016. https://doi.org/10.1155/2016/7530942.

Article CAS Google Scholar

Moradi S, Asgari S, Baharvand H. Concise review: harmonies played by microRNAs in cell fate reprogramming. Stem Cells. 2014;32:315.

CAS PubMed Article Google Scholar

Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, et al. A small-molecule inhibitor of TGF- signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell. 2009;5:491503.

CAS PubMed PubMed Central Article Google Scholar

Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26:7957.

CAS PubMed PubMed Central Article Google Scholar

Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res. 2011;21:196204.

CAS PubMed Article Google Scholar

Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341:6514.

CAS PubMed Article Google Scholar

Moradi S, Sharifi-Zarchi A, Ahmadi A, Mollamohammadi S, Stubenvoll A, Gunther S, et al. Small RNA sequencing reveals Dlk1-Dio3 locus-embedded MicroRNAs as major drivers of ground-state pluripotency. Stem Cell Rep. 2017;9:208196.

CAS Article Google Scholar

Greve TS, Judson RL, Blelloch R. MicroRNA control of mouse and human pluripotent stem cell behavior. Ann Rev Cell Dev Biol. 2013;29:21339.

CAS Article Google Scholar

Moradi S, Braun T, Baharvand H. miR-302b-3p promotes self-renewal properties in leukemia inhibitory factor-withdrawn embryonic stem cells. Cell J. 2018;20:6172.

PubMed Google Scholar

Lee YJ, Ramakrishna S, Chauhan H, Park WS, Hong S-H, Kim K-S. Dissecting microRNA-mediated regulation of stemness, reprogramming, and pluripotency. Cell Regen. 2016;5:2.

Article CAS Google Scholar

Hassani SN, Moradi S, Taleahmad S, Braun T, Baharvand H. Transition of inner cell mass to embryonic stem cells: mechanisms, facts, and hypotheses. Cell Mol Life Sci. 2019;76:87392.

CAS PubMed Article Google Scholar

Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Ctem Cell. 2010;7:6515.

CAS Article Google Scholar

Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Ctem Cell. 2010;6:719.

CAS Article Google Scholar

Xie M, Tang S, Li K, Ding S. Pharmacological reprogramming of somatic cells for regenerative medicine. Acc Chem Res. 2017;50:120211.

CAS PubMed Article Google Scholar

Ma X, Kong L, Zhu S. Reprogramming cell fates by small molecules. Protein Cell. 2017;8:32848.

CAS PubMed PubMed Central Article Google Scholar

Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell. 2013;13:24654.

CAS PubMed Article Google Scholar

Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun. 2010;394:18993.

CAS PubMed Article PubMed Central Google Scholar

Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19:9981004.

CAS PubMed PubMed Central Article Google Scholar

Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:637.

CAS PubMed PubMed Central Article Google Scholar

Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010;7:52131.

CAS PubMed Article PubMed Central Google Scholar

Tompkins JD, Hall C, Chen VC, Li AX, Wu X, Hsu D, et al. Epigenetic stability, adaptability, and reversibility in human embryonic stem cells. Proc Natl Acad Sci U S A. 2012;109:125449.

CAS PubMed PubMed Central Article Google Scholar

Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29:113244.

CAS PubMed Article PubMed Central Google Scholar

Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013;13:14959.

CAS PubMed PubMed Central Article Google Scholar

Steyer B, Bu Q, Cory E, Jiang K, Duong S, Sinha D, et al. Scarless genome editing of human pluripotent stem cells via transient puromycin selection. Stem Cell Rep. 2018;10:64254.

CAS Article Google Scholar

Giacalone JC, Sharma TP, Burnight ER, Fingert JF, Mullins RF, Stone EM, et al. CRISPR-Cas9-based genome editing of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. 2018;44:5B7.

PubMed PubMed Central Google Scholar

Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4:e264.

CAS PubMed PubMed Central Article Google Scholar

Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther. 2001;12:30314.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Rep. 2016;6:78797.

Original post:
Research and therapy with induced pluripotent stem cells ...

IPS Cell Therapy Comments Off on Research and therapy with induced pluripotent stem cells … | July 8th, 2020

After case studies of COVID-19, researchers from the Max Planck Institute of Experimental Medicine in Gttingen, Germany, believe that erythropoietin (EPO) could be used to treat COVID-19 patients. A go-to for many dopers in endurance sports, EPO stimulates the production of red blood cells, which can help with oxygen supply in a users brain and muscles. The team of Mac Planck researchers are planning a clinical trial to take a more in-depth look at EPO and its effects on the coronavirus, and they have outlined their reasoning in an articleon the institutes website.

The German team of researchers cite a COVID-19 case from Iran which occurred in March. The patient was infected with the coronavirus, but doctors noted that they also had poor blood values. To combat this, the patient was prescribed EPO in addition to the regular care for COVID-19. Just a week after starting the EPO treatment, the patient was well enough to return home.

RELATED: Ottawa Marathon third-place finisher provisionally suspended for EPO

Researchers also point to South American populations that live at high altitudes, where severe illnesses are rarer than in lower regions. The Mac Planck Institute team writes that this may be because people living at higher altitudes form more EPO and are better adapted to oxygen deficiency because they have more red blood cells.

According to the article, experiments on animals have shown that EPO affectsparts of the brain stem and spinal cord that control breathing. As a result, the researchers write, breathing improves when there is an oxygen deficiency. EPO also has an anti-inflammatory effect on immune cells and could thus attenuate the frequently exaggerated immune response in COVID-19 patients.

RELATED: WADA to fund anti-doping project piloting artificial intelligence

Dr. Hannelore Ehrenreich, one of the researchers on the German team, notes the importance of determining whether EPO could be an effective treatment for the coronavirus.

Because COVID-19 can have such severe health-related consequences, we must investigate any evidence of a protective effect of EPO, Ehrenreich says. After all, there is currently neither a vaccine nor a medication for the disease. We are therefore preparing a proof-of-concept study to investigate the effect of EPO on COVID-19 in humans. The clinical trial will see severely ill COVID-19 patients receiving EPO to see if it can alleviate severe disease progression.

RELATED: More than half of Bahrains athletics medals are tainted by doping scandals

Following the release of the Max Planck article, running coach Steve Magness tweeted, Just waiting for some athlete or coach trying to get a TUE for taking EPO for a mild COVID case. TUE stands for Therapeutic Use Exemption, which allows athletes to use banned substances for legitimate medical reasons. Magnesss tweet had the feel of a joke, but theres a ring of truth to it. Dopers will do a lot to get away with cheating, and if using EPO to treat COVID-19 becomes a widespread treatment, some athletes might actually take advantage of it.

Read this article:
Could EPO be used to treat COVID-19? - Canadian Running Magazine

Spinal Cord Stem Cells Comments Off on Could EPO be used to treat COVID-19? – Canadian Running Magazine | July 8th, 2020

As reported in an eye-opening new research paper, scientists have created tiny human livers out of human skin cells before successfully transplanting them into rats.

What we are planning to do is to start making mini human organs that are universal, explained the papers co-author, Alejandro Soto-Gutirrez, from the University of Pittsburgh.That would change the paradigm of transplants.

The science-fiction-like procedure was done by taking adult skin cells and genetically altering certain genes and transcription factors to create what are known as pluripotent stem cells.

It starts with human skin cells called fibroblasts, in 2006 the pioneering field of genetic-editing led scientists to discover that they can simply take any cell from a living adult and turn it into a pluripotent stem cell.

Pluri, meaning plurality, indicates its ability to carry the genetic code of all organ types, which is how they can become liver cells.

RELATED: For the First Time in the US, Surgeons Pump New Life into Dead Donor Heart for Life-Saving Transplant

According to the Mayo Clinic, the number of people on current waiting lists for liver transplants far exceeds the number of available liver donors. The cost is just as high: the medical journal Inverse reports the average cost of a transplant, accounting for the entire procedure, is about $812,000.

New technologies always reduce the cost of existing products (remember how expensive flat screen televisions were?) and a new paradigm of made-to-order fabrication of organs would likely fulfill all the demand for transplants while lowering the cost at the same time.

As fascinating as it is a little unsettling, the science took a decade to perfect, but is far still from human trials. The tiny organs from human cells continued working normally after they were transplanted into rats bred to have suppressed immune systems otherwise the body would reject the foreign organ.

RELATED: Game-Changing Approval of Liver Transplant Procedure Expected to Halve the Waiting List

The method and associated technology could produce part-time liver grafts, that could prolong the lives of people waiting on the transplant list.

The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant, Soto-Gutirrez told Inverse. For instance, in acute liver failure, you might just need a hepatic boost for a while, instead of a whole new liver.

(File photo by OPCW Laboratory in Rijswijk, CC license)

YOUR Friends May Be On The Waiting List For Good NewsShare on Social Media

See the rest here:
Dream of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells - Good News Network

Skin Stem Cells Comments Off on Dream of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells – Good News Network | July 7th, 2020

A man undergoes a rapid HIV test. (CLAUDIO REYES/AFP via Getty)

In a major leap forward in the search for a HIV/AIDS cure, a person has been cured of HIV using a cocktail of medicines in what activists have dubbed a breakthrough as exciting as it was unexpected.

HIV, known as human immunodeficiency virus, hobbles peoples immune systems leaving them more vulnerable to once everyday diseases.

In a new study, presented Tuesday (July 7) at the International AIDS conference 2020, a patient on a relatively simple antiretroviral drugregimen was given a medicine commonly used to treat skin cancer.

Previous milestones of individuals HIV appearing to go into long-term remission resulted from bone-marrow transplants given to infected patients. Similarly, the transplants were intended to treat cancer in the patients, not HIV.

But bone-marrow transplants on top of being costly are unlikely to be realistic or reliable treatment options and are, at times, riddled with risk. Yet, this case involved no invasive medical procedures.

As a result, experts told PinkNews, while they are wearily calling it a cure for the virus, it is difficult how to define the word when instances of the virus demise are so few.

Moreover, they said, caution must be exercised in pivoting the case as a success, as scientists must assess whether the outcome can be replicated.

And while the HIV epidemic continues, advocates have warned that the emergence of the coronavirus pandemic its continually sweeping infection rates and how it is vacuuming the attention of scientists and healthcare officials will no doubt knock back success made in recent years.

Dr Andrea Savarino, of the Instituto Superiore di Sanit in Rome, Italy, explained to HIV advocacy group aidsmap during a video call seen by PinkNews that the patient, one of five, was given an experimental drug commonly used as a skin cancer preventative called Nicotinamide as part of the study.

The medicine boosts the immune system, and some academics have demonstrated how Nicotinamide inhibits advanced stages of HIVinfection in cell culture and works on multiple mechanisms to reel back HIV, Savarino said.

By the end of the study, Savarino said, a common indicator of the virus presence viral DNA was undetectable in the patient. Savarino admitted this was not an optimal marker, but it may give an indication of the size of the viral reservoir.

Researchers have long struggled to find a way to destroy HIV reservoirs clusters of infected immune cells that are not producing new HIV but this strategy, Savarino explained, may provide a possible blueprint.

Even after the patient was taken off of his antiretrovirals treatments, the virus did not rebound, the viral DNA was maintained negative, he said. The antibody response decreased over time, if the antibody decreases, it is possible that the virus has stopped its repetition.

The other four patients did rebound, the researcher said.

He stressed that the antibodies made to fight HIV have not disappeared altogether, but did decrease hes still being monitored in order to understand whether the antibodies might disappear as in the case of Mr Timothy Brown,Savarino added.

Brown, often referred to as the Berlin patient, beat HIV with a combination of stem cell transplants and radiotherapy following a diagnosis of leukaemia.

During the trial, only mild side-effects were observed from the cocktail of medicines: No real side-effects were observed from Nicotinamide, which was in-line with previous trials of the medicines impact on cancer.

However, the HIV expert stressed that those living with HIV should not take Nicotinamide in a non-medical setting, being that it is a potent and still experimental medicine.

I really hope that [the study] boosts further research into a HIV cure because it is the first time such a condition is seen, to my knowledge, in a patient under chronic HIV infection, and without having been subjected to a life-threatening medical procedure such as bone marrow transplant, he said.

However, this is our very first experiment, and I wouldnt foresee beyond that.

This was an unexpected result its proof of a concept that we werent really looking out for, Matthew Hodson, executive director of aidsmap, told PinkNews.

We have had effective treatment for HIV for 34 years but 690,000 people died of AIDS last year.

We anticipate that due to COVIDs disruption of health services there will be an even greater number of AIDS-related deaths this year. People around the world are desperately in need of a cure and this case does give us renewed hope.

Although the news is exciting, at this point we have to proceed with caution. We know that a very small number of people can achieve what appears to be remission with antiretroviral drugs alone and it remains possible that this is the case here.

We need to know whether this finding will be replicated in other people, especially as it was not replicated in four other people on the trial.

This particular treatment is relatively inexpensive and, unlike the bone marrow transplant that resulted in previous cure cases, is not especially dangerous to the patient.

This gives me hope that it could be rolled out widely if we found it to work in other people.

Only one person in the small group given this treatment seems to be cured.

Further trials are necessary to find out whether it works for others and which part of the treatment made the difference. This means that it will be some years yet before this treatment will be accessible.

The global fight against AIDS was staggering even before the COVID-19 pandemic, activists admitted, as the United Nations said Sunday that global HIV targets will not be reached.

The organisations AIDS agency said in a report that COVID-19 may hurl progress against the virus back by a decade or even more.

Data from 2019 shows that more than 38 million people worldwide have acquired HIV a million more than in 2018.

UN officials noted that while some 25.7 million people living with HIV were on antiretroviral treatment in 2019 a feat unimaginable a decade prior it still leaves12.6 million not on the life-saving medications.

Visit link:
History made as first person ever is 'cured' of HIV using medication alone - PinkNews

Skin Stem Cells Comments Off on History made as first person ever is ‘cured’ of HIV using medication alone – PinkNews | July 7th, 2020

Oncology is a branch of study and treatment of cancer. Cancer is disease in which abnormal cells grow and divide without control. Oncology drugs help in diagnosis cancer. Some of the causes of cancer are tobacco and smoking, viral infections, genetic causes, carcinogens, bacterial infections, physical activities, eating habits and age. Various types of cancer that can be treated by oncology drugs are blood cancer, endocrine cancer, lung cancer, bone cancer, skin cancer, genitourinary cancer, gastrointestinal cancer, breast cancer, eye cancer, head and neck cancers and gynaecologic cancer. On the basis of treatment, oncology drugs market can be segmented into chemotherapy, immunotherapy, surgery, radiation therapy, stem cell transplant, hormone therapy and others.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/3312

North America, followed by Europe, has the largest market for oncology drugs due to new drug development, government initiatives and developed healthcare infrastructure in this region. Asia is expected to show high growth rate in the oncology drugs market in next few years due to increasing incidence of cancer cases, rise in the use of tobacco products and growth in aging population in the region.

Technological advancement, increasing incidence of various type of cancers, rise in need for R&D activities in cancer and growing concerns over high death rates due to cancer are driving the market for oncology drugs. In addition, introduction of new drugs and therapies for cancer and government support to improve healthcare condition are expected to drive the market for oncology drugs. However, high cost of cancer treatments, strict government regulations, huge investment involvement in the development and clinical trials of the therapies and side effects of cancer treatments are some of the major factors restraining the growth for global oncology drugs market.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/3312

Growing demographics and economies in the developing countries such as China and India are expected to offer good opportunities in oncology drugs market in Asia. In addition, new innovations in cancer drugs and therapies and rise in awareness about the new drugs and therapies available in the market are expected to offer new opportunities for global oncology drugs market. Personalized medicines, increasing number of mergers and acquisitions, new product launches and rise in number of collaborations and partnerships are some of the trends that have been observed in global oncology drugs market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/3312

Some of the major companies operating in the global oncology drugs market are

Originally posted here:
Growing Demand for Oncology Drugs Market to Significantly Increase Revenues Through 2020 - Jewish Life News

Skin Stem Cells Comments Off on Growing Demand for Oncology Drugs Market to Significantly Increase Revenues Through 2020 – Jewish Life News | July 7th, 2020

Cosmetic Skin CareMarketBusiness Insights and Updates:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global Cosmetic Skin CareMarket Industry Trends and Forecast to 2026].The new report on the worldwide Cosmetic Skin CareMarketis committed to fulfilling the necessities of the clients by giving them thorough insights into the Market. The various providers involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.The reports provide Insightful information to the clients enhancing their basic leadership capacity identified.Exclusive information offered in this report is collected by analysis and trade consultants.

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026.

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market

Thestudy considers the Cosmetic Skin CareMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the Cosmetic Skin CareMarketare:LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd

By Product

By Application

By Gender

By Distribution Channel

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-cosmetic-skin-care-market

Based on regions, the Cosmetic Skin CareMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for Cosmetic Skin CareMarket:

Enquire Here For Discount Or Cosmetic Skin CareMarket Report Customization@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.We ponder into the heterogeneous Markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the Markettrends. Data Bridge delves into the Markets across Asia, North America, South America, Africa to name few.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818UK: +44 208 089 1725Hong Kong: +852 819+2 7475Email: [emailprotected]

Read the original here:
Global Cosmetic Skin Care Market Updates, Future Growth, Business Prospects, Forthcoming Developments by Forecast to 2026 - 3rd Watch News

Skin Stem Cells Comments Off on Global Cosmetic Skin Care Market Updates, Future Growth, Business Prospects, Forthcoming Developments by Forecast to 2026 – 3rd Watch News | July 7th, 2020

From Netdoctor

Lymphoma, a type of blood cancer, is the fifth most common cancer in the UK. Lymphomas can be hard to diagnose and with sixty different types, the treatments vary hugely from a watch and wait option to intensive chemotherapy, radiotherapy and even stem cell transplants. People can live for many years with lymphomas so lets look at how they present and what the treatment options are.

Lymphoma is a cancer of lymphocyte cells. Lymphocytes are one of our white blood cells and they play an important role in helping our body to fight off infection. They are present in lymph fluid which circulates around the body via a network of lymph nodes and lymph vessels which form the lymphatic system.

It is common for lymph nodes (also called lymph glands) to swell up when you have an infection. For example, you may notice swollen glands in your neck when you have a sore throat. The glands shrink back down again as the infection clears.

In lymphoma, something happens to the DNA of the lymphocytes which results in the lymphocytes behaving abnormally, they reproduce and multiply in an uncontrolled way. Large numbers of lymphocytes mean that the lymph nodes become congested and swollen without the presence of infection.

There are different type of lymphocyte cells and around sixty different types of lymphoma but they can be divided into two groups:

Non-Hodgkin can be further divided into:

People of any age can get lymphoma, including children. Hodgkin lymphoma occurs most commonly in people in their early twenties and in the over seventies. It affects around 2,000 people each year in the UK. Non-Hodgkin lymphoma is more common affecting around 14,000 people each year, a third of whom are over the age of 75.

The causes of lymphoma are largely unknown. There may be an inherited genetic mutation which causes the DNA to wrongly instruct the lymphocytes to multiply but its not known for certain if lymphoma runs in families.

Whilst it doesnt point to the cause, certain people are at higher risk of developing lymphoma. These include people who have a suppressed immune system. The suppression may come from the presence of a medical condition which directly affects the immune system such as HIV or from taking an immune suppressing medication. People who have previously been infected by the Epstein Barr virus (responsible for glandular fever) also seem to be at higher risk of lymphoma.

Because some of the symptoms of lymphoma such as swollen nodes and fatigue are common, it can be hard to diagnose lymphoma. Superficial lymph nodes in the neck and armpits are easy to feel but many nodes lie deep within the chest or abdomen and cant be seen or felt.

The most common symptoms of lymphoma are:

These are most commonly in the neck, armpits and groin area. Smooth, rubbery lumps can be felt. They arent usually painful and gradually enlarge although they may go up and down in a low grade, non-Hodgkin lymphoma.

If you have swollen glands that have persisted for over two to three weeks or are getting progressively bigger, then see your doctor.

Photo credit: Christopher Futcher - Getty Images

The following generalised symptoms, also called systemic symptoms may be present:

Story continues

When lymph nodes become enlarged they can press on the body tissues surrounding them resulting in a variety of symptoms depending on the location of the nodes. These include:

Some people may have only one symptom, whereas others will have multiple. Similarly, some people may become rapidly very unwell whilst others have a slower, milder form of lymphoma. The variety is huge due to the many different types and locations of lymphoma.

When you feel unwell or notice swollen glands, your first contact is usually with your GP. He or she will not be able to make a diagnosis of lymphoma but may have suspicions based on listening to your explanation of your symptoms and after examining you.

Blood tests will usually be ordered. These include a Full Blood Count (FBC) which gives details of the number of white blood cells, including lymphocytes in your blood. It cannot however give a diagnosis of lymphoma. To reach this you will be referred to a specialist who will arrange specific tests to not only confirm lymphoma but also to work out how advanced the lymphoma is. These include a biopsy where a sample of the tissue from a gland (or commonly a whole gland) is removed and examined under the microscope. Scans such as CT scans, ultrasound scans and X-rays all help to diagnose lymphoma and determine the best treatment plan.

Once the diagnosis has been made, the doctor will find out what stage the lymphoma is at. This means working out which parts of the body are affected and how advanced the disease is. Staging helps to plan the right treatment.

The following staging is for adults with Hodgkin and non-Hodgkin lymphoma. The staging is different in children

Stage 1 only one group of lymph nodes is affected

Stage 2 two groups of lymph nodes are affected but they are both on the same side of the diaphragm e.g. in the neck and armpit

Stage 3 Lymph nodes on both sides of the diaphragm are affected e.g. neck, armpit and groin

Stage 4 Lymphoma has spread to organs outside of the lymphatic system e.g. lungs, liver

Photo credit: Peathegee Inc - Getty Images

The treatment plan for lymphoma varies according to the type and stage of lymphoma however factors such as age, other medical conditions and general health can influence how effective and well tolerated treatment is.

Treatment plans are usually drawn up after a Multi-Disciplinary Team meeting. This is a discussion between a collection of specialists who all use their expertise and previous experience to determine the best course of action for each individual patient.

The aim of treatment is to push the lymphoma into complete remission where there is no evidence that it is still present in the body and to prevent relapses. Sometimes where the lymphoma is a low grade, non-Hodgkin type, the aim is for a partial remission, quietening the disease. In this situation, sometimes treatment isnt offered immediately and a watch and wait approach is taken.

Treatment options include:

The charity Lymphoma action states, In the UK, no alternative therapies are registered for the treatment of lymphoma. There is no evidence that they are effective and they are not recommended by the NHS. Although not recommended as a treatment, many patients gain benefit from complementary therapies alongside their medical treatment. Therapies such as massage, aromatherapy, meditation and mindfulness, can all help to lower stress and anxiety and improve wellbeing and quality of life.

Most cases of lymphoma are treatable.

In England, approximately 75 per cent of people with Hodgkin lymphoma will survive for ten years or more. Younger people and those who are diagnosed earliest have the best survival rates.

The survival rate for non-Hodgkin lymphoma has tripled in the last 40 years in the UK and almost two thirds of people will survive beyond ten years. The survival rates are highest in young people and 9 in 10 people diagnosed with non-Hodgkin lymphoma between the ages of 15 and 39 will survive for more than five years.

*stats from Cancer Research UK https://www.cancerresearchuk.org

Lymphoma action

Blood Cancer UK

Last medically reviewed: 08-07-2020

You Might Also Like

Read this article:
What is lymphoma? Symptoms, causes and diagnosis - Yahoo Lifestyle UK

Skin Stem Cells Comments Off on What is lymphoma? Symptoms, causes and diagnosis – Yahoo Lifestyle UK | July 7th, 2020

CAR-T treatments and other immunotherapies have changed the treatment of some blood cancers, but they can target healthy cells as well as cancer cells, causing nasty side effects. Vor Biopharma is working on an engineered stem cell solution, and its raised $110 million to move its lead program into the clinic.

The Cambridge, Massachusetts-based company is developing the treatment, VOR33, for patients with acute myeloid leukemia (AML) whose disease has worsened despite undergoing chemotherapy or a stem cell transplant.

Thats the setting in which a lot of targeted agents are used. The trouble is, a great number of the targeted agents tend to failnot because they are not efficacious, but because the drug is too toxic for the patients bone marrow, Vor CEO Robert Ang told Fierce Biotech.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The drugs home in on healthy cells as well as cancerous ones because they express the same proteins. This leads to myelosuppression, which means the bone marrow doesnt make enough white blood cells, platelets or red blood cells for the patient to survive, Ang said.

RELATED: Neon CBO Robert Ang jumps ship to take the helm at Vor Biopharma

Vors treatment is made from hematopoietic, or blood-forming, stem cells from healthy donors. The company uses gene editing to get rid of cancer drug targets in those cells that are biologically redundant, which means deleting them doesnt cause any harm. That target is CD33, in the case of VOR33.

Were trying to make the marrow treatment resistant such that the only cells that are expressing CD33 should be cancer cells, Ang said. We should be able to target them much more specifically, while minimizing the collateral damage that typically happens with these drugs.

RELATED: 5AM, JJDC get in on $42M series A round for cell therapy player Vor Biopharma

Vor believes its treatments could boost the reach of targeted therapies by improving their efficacy and increasing the amount of time patients can undergo those treatments.

And thats not all. In addition to protecting these transplants and the blood cells they produce from targeted drugs, Vor thinks its approach could change the way we think about bone marrow transplant.

To some degree, transplants have been relatively decentralized and less controlled A lot of hospitals develop their own unique practices as to what they think works and how to handle cells and process them, Ang said. Our product will be regulated by the FDA, so we will be able to provide controls and the proper manufacturing steps to ensure were making the best quality product for patients.

The series B will push VOR33 into clinical trials in the first half of 2021, a target the companys on track to meet despite the COVID-19 pandemic. And Vor plans to expand its portfolio beyond CD33, starting with an umbrella of targets in the myeloid space, namely in acute myeloid leukemia, myelodysplastic syndromes and related diseases.

But we are also looking beyond that to other cancers where there are similar potentially biologically redundant targets we could pursue, said Ang, who took the companys helm in August 2019.

Since then, Vor has grown from a staff of six to 50, and its about to move into new digs in west Cambridge as it moves VOR33 toward the clinic. Its got the backing of RA Capital Management, Fidelity, 5AM Ventures, Johnson & Johnson Innovation, Osage University Partners, PureTech Health, the Pagliuca Family Office and Alexandria Venture Investments to do it all.

Read more here:
Vor bags $110M to move engineered cell therapy into the clinic - FierceBiotech

Bone Marrow Stem Cells Comments Off on Vor bags $110M to move engineered cell therapy into the clinic – FierceBiotech | July 7th, 2020

Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, acell-based therapy forpeople with amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics, the therapys developer, announced.

The Phase 3 trial (NCT03280056), which enrolled about 200 participants, is underway at six U.S. sites: the University of California, Irvine;Cedars-Sinai Medical Center;California Pacific Medical Center;Massachusetts General Hospital; the University of Massachusetts Medical School; and the Mayo Clinic.

Patients were randomly assigned to either three doses of NurOwn or a placebo, both administered every other month by injections directly into the spinal canal (intrathecal) over a period of four months.

The studys main goal is to assess the safety and efficacy of NurOwn, as measured by changes in the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) score seen at 28 weeks (seven months) following the first treatment. ALSFRS-R assess such daily life abilities as swallowing, speaking, dressing and washing oneself, climbing stairs, and turning over in bed.

Secondary goals include treatment effects on the levels of several disease biomarkers, as found in samples of patients blood and cerebrospinal fluid (the liquid circulating in the brain and spinal cord).

BrainStorm expects top-line trial data to be available before the end of the year.

Completion of participant dosing in this clinical trial is an important milestone and brings us a step closer to potentially filing a biologics license application to make MSC-NTF cells [NurOwn] available to people with ALS, Chaim Lebovits, CEO of BrainStorm, said in the companyspress release.

NurOwn is a cell-based therapy that usesmesenchymal stem cells (MSCs) cells that are able to give rise to nearly all tissues found in the body, including bones, muscles, and connective tissue isolated from a patients own bone marrow.

After isolation, MSCs are grown in a lab dish and differentiated into cells that produce high levels of neurotrophic factors compounds that promote the growth and survival of nerve cells. The modified cells are then returned to patients through an injection into spinal canal.

Brainstorm is also investigating the potential of NurOwn treat other neurological disorders, including multiple sclerosis (MS), Huntingtons disease, Parkinsons disease, and autism spectrum disorder.

The open-label Phase 2 trial (NCT03799718) assessing three doses of NurOwn in people with progressive MSmay still be recruitingat two sites in the U.S. The cell-based therapy has not yet entered clinical testing for other disorders.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 0

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Read more from the original source:
200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy - ALS News Today

Bone Marrow Stem Cells Comments Off on 200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy – ALS News Today | July 7th, 2020

Hematopoietic Stem Cells Transplantation (HSCT) Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Hematopoietic Stem Cells Transplantation (HSCT) industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Hematopoietic Stem Cells Transplantation (HSCT) Market describe Hematopoietic Stem Cells Transplantation (HSCT) Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market:Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Hematopoietic Stem Cells Transplantation (HSCT) Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Summary of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Hematopoietic Stem Cells Transplantation (HSCT) market foreach application, including-

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Autologous Transplant Allogenic Transplant

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

Important Hematopoietic Stem Cells Transplantation (HSCT) Market Data Available In This Report:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Read more here:
Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 - 3rd Watch News

Bone Marrow Stem Cells Comments Off on Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 – 3rd Watch News | July 7th, 2020

ONE simple act could save this little girl's life.

Little Shahera Khan has a fault with her immune system that means her body can't produce enough white blood cells.

3

It means the toddler is susceptible to infections, meaning a seemingly innocuous bug could kill her.

Shahera's life is very different to those of other tot's her age.

She can't go to nursery, make friends or really interact with too many other kids, for fear of picking up infections.

While she loves to play with her big brother, Amaan, five, she has to take daily medication and has blood transfusions each week.

If she picks up a common cold or cough, it can leave her in hospital for days while her tiny body fights the bacteria or virus.

Now, her parents are pleading for help from strangers, to offer their little girl a chance at a normal life.

Shahera's only hope of growing up like her peers is a stem cell transplant.

Speaking to The Sun her Mum Amina said she just wants her daughter to get better and to lead a normal life.

Shahera was born a healthy child and she was okay when she was small.

She picked up bronchiolitis when she was eight months old and had to be hospitalised. We were there for a week and she also picked up an ear and nose infection.

A lot of people say she has been through the wars and she has, she hasnt had an easy childhood and theres always something new with her illness

Amina, who lives in Croydon with Shahera, her husband and Sharehas little brother said that she had Shahera at home for just a couple of days before she had to go back to hospital due to coughing fits.

She recovered at home but within two weeks the family were sent a letter that detailed she had low immunity.

Amina said that little Shahera had a rash on her face and said doctors then had to do a biopsy.

They were scratching their heads really. After a biopsy they found that she was an unusual case.

3

Her skin was pretty bad at that point and they gave her steroids and antibiotics.

At the Evelina hospital they ran further tests on Shahera, but sadly she then had to be hospitalised for bacterial sepsis.

Amina said that all of this happened during the 2018 World Cup and said she remembers it so well as temperatures were soaring and she was trying to control little Shaheras temperature.

She was so thirsty and her temperature was 38/39C.

How to join the stem cell register

Little Shahera needs a stem cell donor - here's how you can register

You can join the stem cell register online. All you need to do is fill out a registration form and you will be sent out some swabs.

You will need to take some samples, usually from the inside of your mouth and then send them back. As soon as they are received you'll be added to the register.

You'll remain on the register until you are 61-years-old.

If you are a match for someone in need charities such as Anthony Nolan will help guide you through the process.

Around 90 per cent of people are able to donate via their blood stream with 10 per cent donating from bone marrow while under general anaesthetic.

To find out more and to register you can visit the below sites:

Then the hospital found that one of her white blood cells was completely wiped out, she was very sick and it was at that point that the doctors mentioned a bone marrow transplant.

Once again Shahera was allowed to return home and she made a good recovery.

Then when she was just one her rash appeared again and more tests found that she had a rare immunodeficiency.

Shahera now has antibody immunoglobulin treatments every week and Amina said this makes a big difference to her quality of life.

3

The issue now Amina says, is that doctors need to find a way to continue to treat Shahera so she can do all the things that other little girls can.

Doctors have given the family several months to find a donor and have said the transplant could take place as early as next spring.

Finding a donor though will be a struggle for the family as just 20 per cent of patients from BAME backgrounds find the best possible donor match.

This is in comparison to 69 per cent for people with white European heritage.

Finding a donor would be a big relief for us, because hopefully it will maker her better

Shahera is of Bangladeshi origin and Amina said its difficult for the family to find someone from their community.

We are part of her journey and it has been difficult but we have been very patient and we are still working with consultants and professors.

At the moment she is doing as well as she can be and she has been shielding due to Covid-19.

Finding a donor would be a big relief for us, because hopefully it will maker her better.

Amina said that the family are not only campaigning to find a donor for Shahera but for others in the same situation.

What is immunoglobulin therapy?

Little Shahera has to have antibody immunoglobulin treatments to keep her well

It is a blood-based treatment that contains antibodies in order to fight against infections.

People are given this treatment when their immune systems do not produce enough antibodies.

Some patients are at a higher risk than others.

Charity PID UK states: "Clinical trials have shown that for people with immune deficiency, immunoglobulin treatments result in fewer infections, and those infections that do occur tend to be less serious.

"There is also evidence that people with immune deficiency are more likely to enjoy good health over many years if they receive immunoglobulin correctly. Finally, your wellbeing and your energy levels are likely to be better if you are on immunoglobulin.

"It may take several months before you feel these benefits.

Everything has been put on hold because of Covid but donating is such a simple process.

A lot of people have misconceptions about stem cell donation, but donors can save lives.

Due to the coronavirus lockdown little Shahera has spent lots of quality time with her family.

Amina said she is doing well and has enjoyed spending even more time with her older brother.

She likes to play cops and robbers and fireman Sam but she also enjoys doing girly things too like looking after her dolls.

Now that Shahera is a little bit older, Amina said she is more aware of her rash and will sometimes look at it and point.

She is very aware of the transfusions and understands what is happening and she is very well known in the ward.

She doesnt really cry when they prepare her for transfusions.

A lot of people say she has been through the wars and she has, she hasnt had an easy childhood and theres always something new with her illness.

Exclusive

SILVER LOFT LININGHomeowners to get 5,000 vouchers to insulate homes under green scheme

KIDS ARE ALL RIGHTGovt to subsidise the wages of under-25s to help 350,000 find jobs

SHOWDOWNDepp 'called himself "the monster" when he attacked Amber Heard in violent rages'

STAMPED OUTRishi Sunak to cut stamp duty TOMORROW after fears of stalled housing market

BAT OUT OF HELLPic of human-sized bat is NOT fakebut still may not be as it seems

Latest

HOPE SPREADSCorona deaths fall in all but one area of England & Wales as toll rises by 155

But shes a tough little girl and she is doing really well.

Sarah Rogers, register development manager at Anthony Nolan says: Little Shahera wants to go to nursery, learn and make more friends just like other toddlers olds across the UK. For this to happen she needs a stranger to donate their stem cells.

"If youre aged 16-30 you can join the register online and well send you a cheek swab in the post.

"If youre found to be a match for a patient, you could donate your stem cells and give hope to families like Shaheras. Your support could help us give a patient, their family and their friends a second chance of life."

Continued here:
One common infection could kill our baby girl but one simple act could change her life forever - The Sun

Bone Marrow Stem Cells Comments Off on One common infection could kill our baby girl but one simple act could change her life forever – The Sun | July 7th, 2020

The FDA has put a phase 1 trial of Cellectis off-the-shelf CAR-T therapy UCARTCS1A on clinical hold after learning of a death in the study. Cellectis said the multiple myeloma patient suffered a cardiac arrest after receiving the highest dose of the anti-CS1 allogeneic CAR-T.

Before joining the Cellectis trial, the patient underwent multiple prior lines of treatment, including with autologous CAR-T cells, without success. In the Cellectis trial, the patient was the first person to receive the higher, 3 million cells per kilogram dose of UCARTCS1A. The patient experienced cytokine release syndrome of undisclosed severity and died of a cardiac arrest 25 days after treatment.

The FDA has placed the trial on clinical hold while Cellectis evaluates the case. According to Cellectis, plans were already afoot to expand the lower, 1 million cells per kilogram dose cohort before the patient death. Preliminary data suggest 1 million cells per kilogram may be the phase 2 dose.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

There are signs the lower dose also has some safety issues. Analysts at Jefferies think investigators gave one or more of the three low-dose patients rituximab to activate the CAR-T safety switch. Work is underway to update the phase 1 protocol to mitigate the potential risks posed by UCARTCS1A.

The modifications may include increased monitoring of parameters related to cytokines. The Jefferies analysts think Cellectis should exclude patients previously treated with anti-BCMA CAR-Ts, such as Johnson & Johnsons JNJ-4528, due to risks related to back-to-back rounds of lymphodepletion, but note that management at the biotech think it is important to enroll that pre-treated population.

In a follow-up note, the analysts identified the use of cyclophosphamide, a chemotherapy drug, in the lymphodepletion regimen as a potential cause of the cardiac arrest. The argument is based on a 2017 paper that describes the case of a patient who died of acute heart failure after receiving a high dose of cyclophosphamide as part of an autologous stem cell transplantation treatment.

Many patients receive cyclophosphamide without suffering cardiac complications, but the analysts see reasons to think the subject enrolled in the Cellectis trial may have been at higher risk. Notably, prior exposure may increase risk, according to the analysts, suggesting the patients previous round of lymphodepletion may have been a factor.

Even if cyclophosphamide is at the heart of the problem, the analysts still think the UCARTCS1A dose is a contributing factor. With patients in the low-dose cohort also experiencing adverse events, the analysts see dosing at below 1 million cells per kilogram as one possible outcome of the situation.

Shares in Cellectis fell 13% in after-hours trading following news of the clinical hold. The value of Allogene Therapeutics, which licensed CAR-T assets that originated at Cellectis, held steady, likely reflecting a belief that the safety issue is limited to UCARTCS1A.

The Jefferies analysts see little or no read-through to other allogeneic programs, noting that the UCARTCS1A trial started at a higher dose than Cellectis two other clinical programs and that Allogene is testing several lymphodepletion regimens. The FDA placed a clinical trial of another Cellectis CAR-T, UCART123, on hold in 2017 after a patient died, but cleared it to resume months later.

Read this article:
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold - FierceBiotech

Cardiac Stem Cells Comments Off on Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold – FierceBiotech | July 7th, 2020

Central nervous system comprises brain and spinal cord, and is responsible for integration of sensory information. Brain is the largest and one of the most complex organs in the human body. It is made up of 100 billion nerves that communicate with 100 trillion synapses. It is responsible for the thought and movement produced by the body. Spinal cord is connected to a section of brain known as brain stem and runs through the spinal canal. The brain processes and interprets sensory information sent from the spinal cord. Brain and spinal cord serve as the primary processing centers for the entire nervous system, and control the working of the body. Neuroprosthetics improves or replaces the function of the central nervous system. Neuroprosthetics, also known as neural prosthetics, are devices implanted in the body that stimulate the function of an organ or organ system that has failed due to disease or injury. It is a brain-computer interface device used to detect and translate neural activity into command sequences for prostheses. Its primary aim is to restore functionality in patients suffering from loss of motor control such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, and stroke. The major types of neuroprosthetics include sensory implants, motor prosthetics, and cognitive prosthetics. Motor prosthetics support the autonomous system and assist in the regulation or stimulation of affected motor functions.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/4160

Similarly, cognitive prosthetics restore the function of brain tissue loss in conditions such as paralysis, Parkinsons disease, traumatic brain injury, and speech deficit. Sensory implants pass information into the bodys sensory areas such as sight or hearing, and it is further classified as auditory (cochlear implant), visual, and spinal cord stimulator. Some key functions of neuroprosthetics include providing hearing, seeing, feeling abilities, pain relief, and restoring damaged brain cells. Cochlear implant is among the most popular neuroprosthetics. In addition, auditory brain stem implant is also a neuroprosthetic meant to improve hearing damage.

North America dominates the global market for neuroprosthetics due to the rising incidence of neurological diseases and growth in geriatric population in the region. Asia is expected to display a high growth rate in the next five years in the global neuroprosthetics market, with China and India being the fastest growing markets in the Asia-Pacific region. Among the key driving forces for the neuroprosthetics market in developing countries are the large pool of patients, increasing awareness about the disease, improving healthcare infrastructure, and rising government funding in the region.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/4160

Increasing prevalence of neurological diseases such as traumatic brain injury, stroke and Parkinsons disease, rise in geriatric population, increase in healthcare expenditure, growing awareness about healthcare, rapid progression of technology, and increasing number of initiatives by various governments and government associations are some key factors driving growth of the global neuroprosthetics market. However, factors such as high cost of devices, reimbursement issues, and adverse effects pose a major restraint to the growth of the global neuroprosthetics market.

Innovative self-charging neural implants that eliminate the need for high risk and costly surgery to replace the discharge battery and controlling machinery with thoughts would help to develop opportunities for the growth of the global neuroprosthetics market. The major companies operating in the global neuroprosthetics market are Boston Scientific Corporation, Cochlear Limited, Medtronic, Inc., Cyberonics, Inc., NDI Medical LLC, NeuroPace, Inc., Nervo Corp., Retina Implant AG, St. Jude Medical, and Sonova Group.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/4160

Growing population and economies in the developing countries such as India and China are expected to drive growth of the prosthetic heart valves market in Asia. In addition, introduction of innovative products with technological advancements, increasing demand for minimally-invasive devices, and rise in incidences of cardiac valve disorders are expected to create opportunities for the global prosthetic heart valves market. Increasing number of mergers and acquisitions, rise in the number of collaborations and partnerships, and product launches are some of the latest trends in the global prosthetic heart valves market.Some of the major companies operating in the global prosthetic heart valves market are Edwards Lifesciences, Medtronic, Abbott Laboratories,ON-X LIFE TECHNOLOGIES, INC.,and St. Jude Medical.In addition, some of the other companies operating in the global prosthetic heart valves market are Sorin Group, CryoLife, LepuMedical, and Braile Biomedica, Ltda.

The rest is here:
Revenue from the Sales of Neuroprosthetics Market to Increase Exponentially During 2015 2021 - 3rd Watch News

Spinal Cord Stem Cells Comments Off on Revenue from the Sales of Neuroprosthetics Market to Increase Exponentially During 2015 2021 – 3rd Watch News | July 7th, 2020

Spinal Fusion Market 2020: Latest Analysis

Chicago, United States:-TheSpinal Fusion market report5 Years Forecast [2020-2025]focuses on theCOVID19 Outbreak Impact analysis of key points influencing the growth of the market. The research report on the Spinal Fusion Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the Spinal Fusion market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Top Players of Spinal Fusion Market are studied:CharterWorthington IndustriesCesca TherapeuticsShengjie Cryogenic EquipmentSichuan mountain verticalQingdao Beol

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Spinal Fusion Market:

What Our Report Offers:

Note: Covid-19 pandemic affects most industries in the globe. Here at acquire market research we offer you comprehensive data of related industry which will help and support your business in all possible ways.Due to the pandemic of COVID-19 businesses have seen a decrease in their profits. While our intention is to help businesses regain their profits we also provide information regarding the COVID-19 virus to help our customers stay safe during the pandemic

Spinal FusionSegmentation by Product

Liquid phaseVapor phase

Spinal FusionSegmentation by Application

Cord Blood Stem Cells CryopreservationOther Stem Cells Cryopreservation

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Benefits of Buying this Market Research Report:

Our exploration specialists acutely ascertain the significant aspects of the global Spinal Fusion market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Spinal Fusion market situation. In this Spinal Fusion report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Spinal Fusion report comprises of primary and secondary data which is exemplified in the form of pie outlines, Spinal Fusion tables, analytical figures, and reference diagrams. The Spinal Fusion report is presented in an efficient way that involves basic dialect, basic Spinal Fusion outline, agreements, and certain facts as per solace and comprehension.

Table of Contents.

Report Overview:It includes major players of the globalkeywordmarket covered in the research study, research scope, and market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the globalkeywordmarket. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the globalkeywordmarket are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the globalkeywordmarket by application, it gives a study on the consumption in the globalkeywordmarket by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the globalkeywordmarket are profiled in this section. The analysts have provided information about their recent developments in the globalkeywordmarket, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the globalkeywordmarket.

Key Findings:This section gives a quick look at the important findings of the research study.

Get Full Customize report @ https://www.reporthive.com/request_customization/2341177

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

The rest is here:
COVID-19 impact on Spinal Fusion Market Growth Analysis, Demand by Regions and Global Forecasts To 2025 | Charter, Worthington Industries, Cesca...

Spinal Cord Stem Cells Comments Off on COVID-19 impact on Spinal Fusion Market Growth Analysis, Demand by Regions and Global Forecasts To 2025 | Charter, Worthington Industries, Cesca… | July 7th, 2020